by Joris | Feb 17, 2026 | Blog, News, Person, SURE Technology
VectorY’s Clinical Milestone and the Shift Towards Experimentally Validated Promoters This week, the ALS community reached a significant milestone. Our partner, VectorY Therapeutics, announced the first patient has been dosed in their Phase 1/2 PIONEER-ALS clinical...
by Joris | Jan 28, 2026 | Blog, News, Person, SURE Technology
JURA Bio and Annogen Announce Research Collaboration to Advance Precision Gene Expression Engineering Through AI-Driven Design and Functional Genomics Partnership brings together JURA’s variational synthesis platform and Annogen’s SuRE™ technology to...
by Joris | Jan 26, 2026 | Application notes, Blog, News, Person, SURE Technology
Twist Webinar: Bespoke Functional Genomics for AI Presented by Dr. Joris van Arensbergen Founder & CEO, Annogen Covered in this Webinar How Annogen generates SuRE™ datasets that support the design of DNA regulatory element How combined with Twist Bioscience’s...
by Joris | Dec 11, 2025 | Blog, News, SURE Technology
Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the...
by Joris | Dec 4, 2025 | Blog, News, SURE Technology
Annogen is excited to confirm our attendance at the upcoming Advanced Therapies Congress, scheduled for March 17th – 18th, 2026, at ExCeL London! We invite you to schedule a meeting to learn more about how Annogen can support your research and development efforts. Our...
by Joris | Dec 4, 2025 | Blog, FACE technology, News, Poster
Annogen is thrilled to announce our participation in the upcoming Plant & Animal Genome (PAG 33) conference, taking place from January 10-14, 2026, in beautiful San Diego, California! As the trusted partner for advanced crop and animal engineering, we are eager to...
